Your browser doesn't support javascript.
Eua for Regen-Cov Now Includes COVID-19 Postexposure Prophylaxis.
Aschenbrenner, Diane S.
  • Aschenbrenner DS; Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch: diane.aschenbrenner@gmail.com.
Am J Nurs ; 121(11): 22, 2021 Nov 01.
Article in English | MEDLINE | ID: covidwho-1475853
ABSTRACT
The emergency use authorization for REGEN-COV (a combination of two monoclonal antibodies, casirivimab and imdevimab) has been revised to include postexposure prophylaxis of COVID-19 in adults and children 12 years of age and older who, if they become COVID-19 positive, are at high risk for severe disease.Prophylaxis with REGEN-COV is not a substitute for vaccination against COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Drug Approval / Post-Exposure Prophylaxis / Antibodies, Monoclonal, Humanized / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Adolescent / Adult / Aged / Child / Humans / Middle aged / Young adult Country/Region as subject: North America Language: English Journal: Am J Nurs Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Drug Approval / Post-Exposure Prophylaxis / Antibodies, Monoclonal, Humanized / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Adolescent / Adult / Aged / Child / Humans / Middle aged / Young adult Country/Region as subject: North America Language: English Journal: Am J Nurs Year: 2021 Document Type: Article